These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 31910099)

  • 21. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J
    Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
    Bakopoulou A
    J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European regulation for therapeutic use of stem cells.
    Ferry N
    Biomed Mater Eng; 2017; 28(s1):S3-S7. PubMed ID: 28372273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PBT assessment using the revised annex XIII of REACH: a comparison with other regulatory frameworks.
    Moermond CT; Janssen MP; de Knecht JA; Montforts MH; Peijnenburg WJ; Zweers PG; Sijm DT
    Integr Environ Assess Manag; 2012 Apr; 8(2):359-71. PubMed ID: 22006646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
    Dejas-Eckertz P; Schäffner G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
    Lodén M; Ungerth L; Serup J
    Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Requirements for Clinical Trials with Gene Therapy and Transplant Products in Switzerland.
    Marti A
    Adv Exp Med Biol; 2015; 871():131-45. PubMed ID: 26374216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From the Integrity of Potency Assays to Safe Clinical Intervention: Legal Perspectives.
    Roslin W; Mansnérus J
    Adv Exp Med Biol; 2023; 1420():151-163. PubMed ID: 37258789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incorporation of a Benefit-Risk Assessment Framework Into the Clinical Overview of Marketing Authorization Applications.
    Wolka A; Warner M; Bullok K; Wang J; Radawski C; Noel R
    Ther Innov Regul Sci; 2016 Jan; 50(1):130-134. PubMed ID: 30236009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [International approaches to the regulation of cell therapy products].
    Piatigorskaia NV; Tulina MA; Aladysheva ZhI; Beregovykh VV
    Vestn Ross Akad Med Nauk; 2013; (8):4-8. PubMed ID: 24340637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Marketing approval and market surveillance of medical devices in Germany: Where does policy integration take place?].
    Lang A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(5-6):320-4. PubMed ID: 25066351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
    Viswanathan S; Bubela T
    Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature.
    Kürzinger ML; Douarin L; Uzun I; El-Haddad C; Hurst W; Juhaeri J; Tcherny-Lessenot S
    Ther Adv Drug Saf; 2020; 11():2042098620976951. PubMed ID: 33343857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex, gender, and pharmaceutical politics: From drug development to marketing.
    Fisher JA; Ronald LM
    Gend Med; 2010 Aug; 7(4):357-70. PubMed ID: 20869636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of new Brazilian legislation for the approval of advanced therapy medicinal products with existing systems in the USA, European Union and Japan.
    Gomes KLG; da Silva RE; da Silva Junior JB; Novaes MRCG
    Cytotherapy; 2022 May; 24(5):557-566. PubMed ID: 35227603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of cell-based therapeutic products intended for human applications in the EU.
    Närhi MO; Nordström K
    Regen Med; 2014 May; 9(3):327-51. PubMed ID: 24935044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.